Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance

Shoichi Maruyama,Yoichiro Ikeda,Shinya Kaname,Noritoshi Kato,Masanori Matsumoto,Yumiko Ishikawa,Akihiko Shimono,Yoshitaka Miyakawa,Masaomi Nangaku,Yugo Shibagaki,Hirokazu Okada

Journal of Nephrology（2024）

引用 0|浏览7

暂无评分

摘要

Eculizumab has been approved for atypical haemolytic-uraemic syndrome (aHUS) in Japan since 2013. Post-marketing surveillance enrolled patients with aHUS who received ≥ 1 dose of eculizumab to assess eculizumab safety and effectiveness. We evaluated serious adverse events and effectiveness endpoints, i.e., haematologic normalization, a decrease of ≥ 25

查看译文

关键词

Atypical haemolytic uraemic syndrome,Thrombotic microangiopathy,Eculizumab,Post-marketing surveillance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要